Charles Schwab Trust Co Has $1.85 Million Stock Holdings in Abbott Laboratories (NYSE:ABT)

Charles Schwab Trust Co lessened its stake in Abbott Laboratories (NYSE:ABT - Free Report) by 14.0% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 13,939 shares of the healthcare product maker's stock after selling 2,267 shares during the period. Charles Schwab Trust Co's holdings in Abbott Laboratories were worth $1,849,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also made changes to their positions in the company. Redwood Park Advisors LLC purchased a new stake in shares of Abbott Laboratories during the 4th quarter worth about $25,000. Noble Wealth Management PBC acquired a new stake in Abbott Laboratories during the 4th quarter worth approximately $26,000. NewSquare Capital LLC increased its holdings in shares of Abbott Laboratories by 78.4% in the 4th quarter. NewSquare Capital LLC now owns 239 shares of the healthcare product maker's stock valued at $27,000 after acquiring an additional 105 shares during the last quarter. WealthTrak Capital Management LLC acquired a new stake in shares of Abbott Laboratories in the fourth quarter valued at approximately $28,000. Finally, Rialto Wealth Management LLC acquired a new stake in Abbott Laboratories during the 4th quarter worth approximately $29,000. Institutional investors own 75.18% of the company's stock.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on the company. Raymond James lifted their price target on Abbott Laboratories from $132.00 to $142.00 and gave the stock an "outperform" rating in a research note on Thursday, April 17th. Wall Street Zen downgraded Abbott Laboratories from a "strong-buy" rating to a "buy" rating in a research note on Wednesday, February 12th. Citigroup lifted their target price on Abbott Laboratories from $135.00 to $160.00 and gave the stock a "buy" rating in a report on Tuesday, March 4th. Jefferies Financial Group lifted their target price on shares of Abbott Laboratories from $135.00 to $137.00 and gave the company a "hold" rating in a research note on Thursday, April 17th. Finally, Wells Fargo & Company upped their price objective on shares of Abbott Laboratories from $136.00 to $147.00 and gave the stock an "overweight" rating in a report on Thursday, April 17th. Four investment analysts have rated the stock with a hold rating, fifteen have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, Abbott Laboratories currently has an average rating of "Moderate Buy" and a consensus target price of $142.59.

Abbott Laboratories Trading Down 0.2%

Abbott Laboratories stock traded down $0.33 during trading hours on Friday, reaching $133.61. 3,866,397 shares of the company's stock traded hands, compared to its average volume of 6,155,649. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.14 and a current ratio of 1.60. Abbott Laboratories has a fifty-two week low of $99.71 and a fifty-two week high of $141.23. The firm's 50 day moving average is $130.71 and its 200-day moving average is $125.66. The firm has a market capitalization of $232.45 billion, a price-to-earnings ratio of 17.46, a PEG ratio of 2.52 and a beta of 0.73.

Abbott Laboratories (NYSE:ABT - Get Free Report) last released its earnings results on Wednesday, April 16th. The healthcare product maker reported $1.09 EPS for the quarter, beating the consensus estimate of $1.07 by $0.02. Abbott Laboratories had a return on equity of 20.74% and a net margin of 31.95%. The firm had revenue of $10.36 billion for the quarter, compared to analysts' expectations of $10.38 billion. On average, analysts predict that Abbott Laboratories will post 5.14 earnings per share for the current year.

Insider Activity

In related news, Director Sally E. Blount sold 2,600 shares of the business's stock in a transaction that occurred on Wednesday, April 30th. The stock was sold at an average price of $129.66, for a total value of $337,116.00. Following the completion of the sale, the director now directly owns 34,058 shares in the company, valued at approximately $4,415,960.28. The trade was a 7.09% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. Insiders own 0.46% of the company's stock.

Abbott Laboratories Company Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.